

**Unaudited Financial Statements**  
**for the Year Ended 31 March 2023**  
**for**  
**DRUGLAB118 LTD**

**Contents of the Financial Statements**  
**for the Year Ended 31 March 2023**

	<b>Page</b>
<b>Company Information</b>	1
<b>Abridged Balance Sheet</b>	2
<b>Notes to the Financial Statements</b>	4
<b>Accountants' Report</b>	6

**DRUGLAB118 LTD**

**Company Information**  
**for the Year Ended 31 March 2023**

**Director:** C Lyon

**Registered office:** 43 Coniscliffe Road  
Darlington  
Co. Durham  
DL3 7EH

**Registered number:** 08447515 (England and Wales)

**Accountants:** Mitchell Gordon LLP  
43 Coniscliffe Road  
Darlington  
Co. Durham  
DL3 7EH

**Abridged Balance Sheet**  
**31 March 2023**

	Notes	31/3/23 £	£	31/3/22 £	£
<b>Fixed assets</b>					
Intangible assets	4		4,841		6,542
<b>Current assets</b>					
Stocks		4,250		-	
Debtors		-		1,211	
Cash at bank and in hand		<u>5,244</u>		<u>21,685</u>	
		9,494		22,896	
<b>Creditors</b>					
Amounts falling due within one year		<u>151,708</u>		<u>159,587</u>	
<b>Net current liabilities</b>			<u>(142,214)</u>		<u>(136,691)</u>
<b>Total assets less current liabilities</b>			<u>(137,373)</u>		<u>(130,149)</u>
<b>Capital and reserves</b>					
Called up share capital			100		100
Retained earnings			<u>(137,473)</u>		<u>(130,249)</u>
<b>Shareholders' funds</b>			<u>(137,373)</u>		<u>(130,149)</u>

The notes form part of these financial statements

**Abridged Balance Sheet - continued**  
**31 March 2023**

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Income Statement and an abridged Balance Sheet for the year ended 31 March 2023 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 17 November 2023 and were signed by:

C Lyon - Director

**Notes to the Financial Statements**  
**for the Year Ended 31 March 2023**

**1. STATUTORY INFORMATION**

Druglab118 Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on the going concern basis of accounting. At the balance sheet date the company's liabilities exceeded its assets by £137,373. The director has confirmed that he will continue to support the company continuing in trade.

**Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

**Intangible assets**

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of five years.

**Stocks**

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 1 (2022 - 1).

**Notes to the Financial Statements - continued**  
**for the Year Ended 31 March 2023**

4. **INTANGIBLE FIXED ASSETS**

	Totals £
<b>COST</b>	
At 1 April 2022	44,476
Additions	<u>1,404</u>
At 31 March 2023	<u>45,880</u>
<b>AMORTISATION</b>	
At 1 April 2022	37,934
Amortisation for year	<u>3,105</u>
At 31 March 2023	<u>41,039</u>
<b>NET BOOK VALUE</b>	
At 31 March 2023	<u>4,841</u>
At 31 March 2022	<u>6,542</u>

5. **DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES**

This balance was interest free and repayable on demand.

**Accountants' Report to the Director**  
**on the Unaudited Financial Statements of**  
**Druglab118 Ltd**

**The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Abridged Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.**

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Druglab118 Ltd for the year ended 31 March 2023 which comprise the Abridged Income Statement, Abridged Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at <http://www.accaglobal.com/rulebook>.

This report is made solely to the director of Druglab118 Ltd in accordance with the terms of our engagement letter dated 31 July 2023. Our work has been undertaken solely to prepare for your approval the financial statements of Druglab118 Ltd and state those matters that we have agreed to state to the director of Druglab118 Ltd in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at <http://www.accaglobal.com/factsheet163>. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its director for our work or for this report.

It is your duty to ensure that Druglab118 Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Druglab118 Ltd. You consider that Druglab118 Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Druglab118 Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Mitchell Gordon LLP  
43 Coniscliffe Road  
Darlington  
Co. Durham  
DL3 7EH

17 November 2023



This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.